母亲因炎症性肠病接受生物制剂治疗的婴儿接种轮状病毒活疫苗似为低风险
本研究评估母体生物制剂暴露对婴儿免疫系统及轮状病毒活疫苗接种安全性的影响。57名暴露婴儿免疫学评估均正常,其中50名接种轮状病毒活疫苗后未报告免疫接种不良事件。结论认为生物制剂暴露婴儿接种轮状病毒活疫苗似为低风险,与循环药物水平无关。
要点
- 57名母体生物制剂暴露婴儿免疫学评估均正常,尽管可检测到药物浓度。
- 50名婴儿接种轮状病毒活疫苗后未报告免疫接种不良事件。
- 生物制剂暴露婴儿接种轮状病毒活疫苗似为低风险,与循环药物水平无关。
核心结论
- 免疫功能检测正常,生物制剂暴露婴儿接种轮状病毒活疫苗似为低风险,与循环药物水平无关。
研究设计与样本
- 本研究为对57名暴露于母体生物制剂的婴儿进行标准化临床评估、药物浓度和免疫功能检测,并记录轮状病毒疫苗特异性不良事件的研究。
主要发现
- 57名婴儿来自52名炎症性肠病母亲,妊娠晚期暴露于英夫利西单抗(n=21)、阿达木单抗(n=19)、维得利珠单抗(n=10)和乌司奴单抗(n=7),分娩时中位孕周39周(四分位距38-39周)。
- 所有婴儿年龄验证的免疫学评估均正常,尽管中位英夫利西单抗浓度为6.1 ug/mL(范围0.4-28.8 ug/mL),阿达木单抗浓度为1.7 ug/mL(范围0.7-7.9 ug/mL),乌司奴单抗浓度为0.6 ug/mL(范围0-1.1),维得利珠单抗在10.7周龄(四分位距9.4-12.4周)时不可检测。
- 50名婴儿接种了轮状病毒活疫苗系列,首剂中位接种年龄为13周,未报告免疫接种不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Biologic therapies in the context of inflammatory bowel disease and pregnancy lead to improved maternal and fetal outcomes. Placental transfer results in detectable drug concentrations in infants. Rotavirus infection results in diarrheal related hospitalizations; however, the live oral vaccine is not currently recommended in biologic exposed infants. The aim of this study was to assess the effect of maternal biologic therapies on the infant immune system and safety of live rotavirus vaccination in biologic-exposed infants. METHODS: Biologic-exposed infants underwent standardized clinical assessments, drug concentration, and immune function testing (complete blood count, differential, immunoglobulin levels, extended B-cell and T-cell subset enumeration, Recent Thymic Emigrants, regulatory T-cell numbers, mitogen stimulation assays, and review of T-cell Receptor Excision Circles in the newborn screen). Rotavirus vaccine-specific adverse effects following immunizations up to 42 days post the last dose of the vaccine series were recorded. RESULTS: There were 57 infants born to 52 mothers with inflammatory bowel disease exposed to infliximab (n = 21), adalimumab (n = 19), vedolizumab (n = 10), and ustekinumab (n = 7) in the third trimester for a median of 39 weeks (interquartile range, 38-39 weeks) at delivery. Immunologic assessments validated for age were normal in all infants despite median infliximab concentrations of 6.1 ug/mL (range, 0.4-28.8 ug/mL), adalimumab concentrations of 1.7 ug/mL (range, 0.7-7.9 ug/mL), ustekinumab concentrations of 0.6 ug/mL (range, 0-1.1), and undetectable for vedolizumab at 10.7 weeks (interquartile range, 9.4-12.4) of age. The live oral rotavirus vaccine series was provided to 50 infants with the first dose given at a median of 13 weeks of age. No adverse effects following immunization were reported. CONCLUSION: Immune function testing was normal, and administration of live rotavirus vaccination appeared low-risk in biologic-exposed infants irrespective of circulating drug levels.
引用
- Ernest-Suarez K, Murguía-Favela LE, Constantinescu C, et al. Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics. Clin Gastroenterol Hepatol. 2024. PMID: 39089515. doi:10.1016/j.cgh.2024.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。